InflaRx N.V.
InflaRx N.V. is testing IFX-1, a monoclonal anti-human complement factor C5a antibody currently under development as treatment for inflammatory conditions and COVID-19 pneumonia.
Rankings by 
National Ranking
41st
in GermanyRegional Ranking
318th
in Western EuropeGlobal Ranking
1451st
worldwide